What is Jw?
Established in 2016, JW Therapeutics is an independent, innovative biotechnology company dedicated to the development, production, and commercialization of cell immunotherapy products. The company has successfully built a leading, comprehensive product development platform for cell immunotherapy, addressing a spectrum of conditions including hematological tumors, solid tumors, and autoimmune diseases. JW Therapeutics' mission is to deliver high-quality, breakthrough cell immunotherapy solutions, offering hope for cures to patients both in China and globally. Furthermore, the company is committed to spearheading the healthy and standardized advancement of the cell immunotherapy industry within China. JW Therapeutics is publicly listed on the Hong Kong Stock Exchange under the code 2126.
How much funding has Jw raised?
Jw has raised a total of $190M across 2 funding rounds:
Series A
$90M
Series B
$100M
Series A (2018): $90M with participation from Temasek
Series B (2020): $100M led by CPE and Mirae Asset
Key Investors in Jw
Temasek
Temasek is a global investment company headquartered in Singapore, established in 1974. It operates as a generational investor, focusing on making a difference with a long-term perspective.
CPE
CPE is an investor participating in the Series B funding round for JW Therapeutics. Further details on their investment focus are not publicly disclosed.
Mirae Asset
Mirae Asset is an investor that participated in JW Therapeutics' Series B financing. Specific details regarding their investment thesis are not available.
What's next for Jw?
The recent major strategic investment, alongside the overall enterprise-level funding JW Therapeutics has attracted, signals a robust growth phase for the company. This significant capital infusion is poised to accelerate the development and commercialization of its cell immunotherapy pipeline, potentially expanding its reach in both domestic and international markets. The company's focus on a comprehensive platform suggests strategic initiatives aimed at solidifying its leadership position and driving innovation within the rapidly evolving field of cell therapy. Future endeavors will likely involve further research and development, clinical trial advancements, and strategic partnerships to bring its promising therapies to patients.
See full Jw company page
